Can a One-Two punch of immune boosters revive cancer treatment?
Disease control
Terminated
This phase 2 trial tests whether combining high-dose IL-2 with nivolumab can shrink tumors in people with advanced melanoma or kidney cancer that has progressed despite prior anti-PD-1 therapy. Participants receive nivolumab and high-dose IL-2 in repeated cycles, and researchers …
Phase: PHASE2 • Sponsor: Gregory Daniels • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC